Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Abaxis Inc    ABAX

ABAXIS INC (ABAX)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 05/18 10:00:00 pm
83.32 USD   -0.48%
05/18ROBBINS ARROYO : Acquisition of Abaxis, Inc. (ABAX) by Zoetis Inc. ..
BU
05/17WEISSLAW LLP : Investigates Abaxis Inc.
PR
05/17ABAXIS : Zoetis fetches Abaxis
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Zoetis to buy veterinary diagnostics firm Abaxis for $1.9 billion

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2018 | 07:56pm CEST
Traders work on the floor of the New York Stock Exchange

(Reuters) - Top animal health company Zoetis Inc will buy Abaxis Inc for $1.9 billion (£1.4 billion), looking to capture a bigger slice of the fast-growing market for diagnostics services that cater to household pets and farm animals.

(Reuters) - Top animal health company Zoetis Inc will buy Abaxis Inc for $1.9 billion (£1.4 billion), looking to capture a bigger slice of the fast-growing market for diagnostics services that cater to household pets and farm animals.

The deal announced Wednesday reflects Zoetis' expectation that the diagnostics category will grow at a faster pace than the broader animal health industry.

Abaxis — which makes blood and urine tests to predict, detect and treat diseases such as heartworm, Lyme disease or tick-borne infections — will also help its New Jersey-based acquirer bolster its presence in overseas markets.

Zoetis faces much lesser competition internationally than in the United States, its Chief Executive Officer Juan Alaix said on a conference call with analysts.

"The characteristic of patients in animal health is that they don't speak. So in our industry, almost every animal getting into clinics needs to have a diagnostic test," Alaix said.

The veterinary diagnostics market worldwide is expected grow to $3.6 billion in 2022 from $2.3 billion in 2017, according to research firm MarketsandMarkets https://www.marketsandmarkets.com/PressReleases/veterinary-diagnostics.asp.

By contrast, the global animal medicines and vaccines market is worth around $30 billion, according to veterinary consultancy Vetnosis.

Much of Zoetis' revenue is driven by its animal dermatology business, and diagnostics contribute just under 1 percent of its overall annual revenue of more than $5 billion.

On Wednesday, Zoetis' shares fell 0.5 percent, while shares of IDEXX Laboratories Inc, Abaxis' biggest competitor, fell 3.7 percent.

"We believe this is a good deal for Zoetis although the valuation seems high," BMO Capital Markets analyst Alex Arfaei said.

Shares of Abaxis rose as much as 16 percent to an all-time high of $83.24, inching past Zoetis' all-cash offer price of $83 per share.

At seven times Abaxis' annual revenue, the price Zoetis is paying is already "pretty steep," said C.L. King and Associates analyst David Westenberg. "If there's another bidder, I don't think Zoetis would go any higher," he said.

However, should there be a rival offer, the companies most likely to make a bid would be Eli Lilly and Co's animal health unit Elanco or candy and pet food company Mars Inc, Westenberg said.

Other possible bidders include dental supply firms Henry Schein Inc and Patterson Companies Inc, which also have animal health divisions, he added.

Zoetis plans to fund the acquisition through cash and new debt. It expects the deal to close before the end of the year and Abaxis to add to its earnings in 2019.

(The story correct a typo in paragraph 3)

(Reporting by Tamara Mathias in Bengaluru; Editing by Anil D'Silva and Sai Sachin Ravikumar)

By Tamara Mathias

Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 0.50% 82.07 Delayed Quote.-2.83%
HENRY SCHEIN -0.47% 71.94 Delayed Quote.3.43%
IDEXX LABORATORIES 2.64% 200.76 Delayed Quote.25.07%
PATTERSON COMPANIES -1.02% 22.43 Delayed Quote.-37.92%
ZOETIS 1.75% 84.4 Delayed Quote.17.16%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABAXIS INC
05/18ROBBINS ARROYO LLP : Acquisition of Abaxis, Inc. (ABAX) by Zoetis Inc. (ZTS) May..
BU
05/17WEISSLAW LLP : Investigates Abaxis Inc.
PR
05/17ABAXIS : Zoetis fetches Abaxis
AQ
05/17ABAXIS INC : Today’s Research Reports on Stocks to Watch: Abaxis, Inc. and Cesca..
AC
05/17ABAXIS, INC. (NASDAQ : ABAX) Files An 8-K Financial Statements and Exhibits
AQ
05/17ABAXIS INC : SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation..
AC
05/16ABAXIS INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/16Abaxis and Macy's climb while Phillips 66, Newfield skid
AQ
05/16Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether..
BU
05/16Zoetis to buy veterinary diagnostics firm Abaxis for $1.9 billion
RE
More news
News from SeekingAlpha
05/18HESKA : Pets Are People Too 
05/16Midday Gainers / Losers (05/16/2018) 
05/16HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (05/16/2018) 
05/16PREMARKET GAINERS AS OF 9 : 05 am (5/16/2018) 
05/16Zoetis to acquire Abaxis for $2B 
Financials ($)
Sales 2019 279 M
EBIT 2019 43,6 M
Net income 2019 35,2 M
Finance 2019 46,1 M
Yield 2019 0,82%
P/E ratio 2019 55,51
P/E ratio 2020 48,62
EV / Sales 2019 6,65x
EV / Sales 2020 6,20x
Capitalization 1 900 M
Chart ABAXIS INC
Duration : Period :
Abaxis Inc Technical Analysis Chart | ABAX | US0025671050 | 4-Traders
Technical analysis trends ABAXIS INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 72,7 $
Spread / Average Target -13%
EPS Revisions
Managers
NameTitle
Clinton H. Severson Chairman & Chief Executive Officer
Donald Peter Wood President & Chief Operating Officer
Ross Taylor CFO, Secretary & VP-Investor Relations
Kenneth P. Aron Chief Technology Officer
Richard J. Bastiani Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABAXIS INC68.26%1 900
THERMO FISHER SCIENTIFIC11.13%84 894
DANAHER CORPORATION8.58%70 402
INTUITIVE SURGICAL25.72%51 880
BOSTON SCIENTIFIC CORPORATION19.48%41 836
ROYAL PHILIPS14.12%40 375